- Home
- Share
- Forum
- Multiple sclerosis Forum
- Research and useful links - Multiple Sclerosis
- Cleveland Researchers Develop A New Treatment for Multiple Sclerosis And Launch a Company to Test It
Patients Multiple sclerosis
Cleveland Researchers Develop A New Treatment for Multiple Sclerosis And Launch a Company to Test It
- 17 views
- 2 times supported
- 2 comments
All comments
LynndMS
07/30/2018 at 4:59 PM
Good advisor
Wow!! This would be a Godsend. I wonder if there are trials or what the cost is ... thank you for posting!!’
suplkr1
Edited on
08/01/2018 at 6:08 AM
Good advisor
I looked into it... here is the company's website https://www.convelotx.com/news/
Give your opinion
Survey
Members are also commenting on...
Articles to discover...

11/26/2018 | Testimonial
Multiple Sclerosis And The Success And Side-Effects With Various Treatments

08/17/2018 | Testimonial
No One Knows What Being Diagnosed with Multiple Sclerosis Is Like, So Maintain A Can-Do Attitude
Subscribe
You wish to be notified of new comments
You have been subscribed
Lee__R
Community managerGood advisor
A team at Case Western Reserve University has come up with a new approach to treating Multiple Sclerosis.
They have also launched a business to bring the new therapy to market.
The company is called Convelo Therapeutics.
Co-founders Paul Tesar and Drew Adams collaborated on research at Case Western Reserve University School of Medicine that focused on restoring the brain cells that produce the protective coating on nerve cells called myelin.
In MS the myelin is stripped away, leading to loss of movement and other impairments for those affected.
Tesar and Adams discovered a set of molecules that allow cells in the brain called oligodendrocytes to repair the damage.
Tesar hopes the new company can bring the drugs from the lab to the bedside.
“Something that Drew and I felt very strongly about was to get this out into the commercial sector into an early-stage company that could develop and discover these and
Investors provided $7.8 million in seed capital to begin the work of testing in humans.
Tesar said the company will also begin development of therapies for brain injuries and Alzheimer’s using the new technology.
MS affects 2.3 million people worldwide.
WKSU